An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent 99mTc-NC100692.
about
Stromal Targets for Fluorescent-Guided Oncologic SurgerySPECT and PET imaging of angiogenesis and arteriogenesis in pre-clinical models of myocardial ischemia and peripheral vascular diseaseMolecular Imaging of Angiogenesis in Cardiac RegenerationNuclear imaging of the breast: translating achievements in instrumentation into clinical useApplication of (68)Ga-PRGD2 PET/CT for αvβ3-integrin imaging of myocardial infarction and stroke.Near-infrared fluorescence imaging of both colorectal cancer and ureters using a low-dose integrin targeted probe.Molecular imaging of angiogenesis with SPECT.Comparison of 99mTc-3PRGD2 integrin receptor imaging with 99mTc-MDP bone scan in diagnosis of bone metastasis in patients with lung cancer: a multicenter study.(99m)Tc-3P-RGD2 micro-single-photon emission computed tomography/computed tomography provides a rational basis for integrin αvβ3-targeted therapy.Imaging key biomarkers of tumor angiogenesisMolecular imaging probes for diagnosis and therapy evaluation of breast cancerRadiometallated peptides for molecular imaging and targeted therapy.Radiolabelled RGD peptides for imaging and therapy.Clinical imaging of tumor angiogenesis.Molecular imaging agents for SPECT (and SPECT/CT).Specific uptake of 99mTc-NC100692, an αvβ3-targeted imaging probe, in subcutaneous and orthotopic tumors.Utility of Tc-PEG4-E[PEG4-c(RGDfK)]2 in Posttherapy Surveillance of Patients with Reelevated Carcinoembryonic Antigen Levels[Status and advances of RGD molecular imaging in lung cancer].
P2860
Q26774497-85F083CF-F228-4046-A8D3-96F2A87D0469Q28066121-40868063-5DBA-4577-BB5C-18E1AAF7C822Q28073273-D9C4D3D6-6F5E-4206-9A0C-8FD303D5DD2AQ30419180-DA87A5C8-3227-4B82-AAD0-DCE12B161EF6Q30832796-3A3E6CEA-384D-4B99-9C77-1AE0028165B8Q34028690-8D146505-874D-4A68-9EC2-ABF1D2B9C529Q34040149-7C7C9DFA-378A-422A-94E6-42C1B8E3CD79Q34388500-15A81801-24E6-4BC9-BEB3-896312E3291EQ34471067-45CC6F62-F722-4626-9471-8CB3FC0766C4Q35999557-650B6752-DBB1-43BD-966F-443F027EBDD1Q36692448-ABE3A1A4-5446-4B17-B3D5-D3A5B3DC8E7CQ37847064-408C6DC1-7266-49B5-BAA6-FF6F9E099732Q37990409-44BDCFD3-5F40-4298-9C09-1A34028A3010Q38059503-EBDF9D29-30E0-458D-9CDF-6ECB3E8A1A26Q38169570-7585C102-1C42-46C3-9A54-2718D6C46310Q39148256-C0E220C2-A845-4562-BCAD-8159A683AE39Q41076553-D18C213E-A40F-4082-AF6C-5CDE4E1D150DQ55465071-882625A7-3250-4B41-B04F-C464988A9AAA
P2860
An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent 99mTc-NC100692.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
An open-label, multicenter, ph ...... imaging agent 99mTc-NC100692.
@en
An open-label, multicenter, ph ...... imaging agent 99mTc-NC100692.
@nl
type
label
An open-label, multicenter, ph ...... imaging agent 99mTc-NC100692.
@en
An open-label, multicenter, ph ...... imaging agent 99mTc-NC100692.
@nl
prefLabel
An open-label, multicenter, ph ...... imaging agent 99mTc-NC100692.
@en
An open-label, multicenter, ph ...... imaging agent 99mTc-NC100692.
@nl
P2093
P1433
P1476
An open-label, multicenter, ph ...... imaging agent 99mTc-NC100692.
@en
P2093
Brian J McParland
Rimma Axelsson
Study Group
Tore Bach-Gansmo
P356
10.3109/02841850903273974
P407
P577
2010-02-01T00:00:00Z